Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.

Peterson LF, Yan M, Zhang DE.

Blood. 2007 May 15;109(10):4392-8. Epub 2007 Feb 6.

2.

A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.

Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, Zhang DE.

Nat Med. 2006 Aug;12(8):945-9. Epub 2006 Jul 30.

PMID:
16892037
3.

AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.

Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K, Zhang DE.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403.

4.

Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.

Ahn EY, Yan M, Malakhova OA, Lo MC, Boyapati A, Ommen HB, Hines R, Hokland P, Zhang DE.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17103-8. doi: 10.1073/pnas.0802696105. Epub 2008 Oct 24.

5.

The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.

Elsässer A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G.

Oncogene. 2003 Aug 28;22(36):5646-57.

PMID:
12944913
6.

Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells.

Li X, Xu YB, Wang Q, Lu Y, Zheng Y, Wang YC, Lübbert M, Zhao KW, Chen GQ.

J Cell Physiol. 2006 Sep;208(3):594-601.

PMID:
16741927
7.

Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.

Berg T, Fliegauf M, Burger J, Staege MS, Liu S, Martinez N, Heidenreich O, Burdach S, Haferlach T, Werner MH, Lübbert M.

Haematologica. 2008 Nov;93(11):1728-33. doi: 10.3324/haematol.13044. Epub 2008 Sep 11.

8.

The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G.

Blood. 2003 Jan 1;101(1):270-7. Epub 2002 Aug 29.

9.
10.

Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis.

Rhoades KL, Hetherington CJ, Rowley JD, Hiebert SW, Nucifora G, Tenen DG, Zhang DE.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11895-900.

11.

Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein.

Zhen T, Wu CF, Liu P, Wu HY, Zhou GB, Lu Y, Liu JX, Liang Y, Li KK, Wang YY, Xie YY, He MM, Cao HM, Zhang WN, Chen LM, Petrie K, Chen SJ, Chen Z.

Sci Transl Med. 2012 Mar 28;4(127):127ra38. doi: 10.1126/scitranslmed.3003562.

12.
13.

Dominant negative effects of the AML1/ETO fusion oncoprotein.

Fenske TS, Pengue G, Graubert TA.

Cell Cycle. 2005 Jan;4(1):33-6. Epub 2005 Jan 19.

PMID:
15611635
14.

The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.

Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, Spiekermann K, Humphries RK, Schnittger S, Kern W, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C.

J Clin Invest. 2005 Aug;115(8):2159-68. Epub 2005 Jul 14.

15.

UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.

Goyama S, Schibler J, Gasilina A, Shrestha M, Lin S, Link KA, Chen J, Whitman SP, Bloomfield CD, Nicolet D, Assi SA, Ptasinska A, Heidenreich O, Bonifer C, Kitamura T, Nassar NN, Mulloy JC.

Leukemia. 2016 Mar;30(3):728-39. doi: 10.1038/leu.2015.275. Epub 2015 Oct 9.

16.

Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.

Li Y, Wang H, Wang X, Jin W, Tan Y, Fang H, Chen S, Chen Z, Wang K.

Blood. 2016 Jan 14;127(2):233-42. doi: 10.1182/blood-2015-03-626671. Epub 2015 Nov 6.

17.

AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.

Hatlen MA, Wang L, Nimer SD.

Front Med. 2012 Sep;6(3):248-62. doi: 10.1007/s11684-012-0206-6. Epub 2012 Aug 9. Review.

PMID:
22875638
18.

The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.

Lo Coco F, Pisegna S, Diverio D.

Haematologica. 1997 May-Jun;82(3):364-70. Review.

19.

Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.

Steffen B, Serve H, Berdel WE, Agrawal S, Linggi B, Büchner T, Hiebert SW, Müller-Tidow C.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8448-53. Epub 2003 Jun 20.

20.

Valproic acid triggers differentiation and apoptosis in AML1/ETO-positive leukemic cells specifically.

Zapotocky M, Mejstrikova E, Smetana K, Stary J, Trka J, Starkova J.

Cancer Lett. 2012 Jun 28;319(2):144-153. doi: 10.1016/j.canlet.2011.12.041. Epub 2012 Jan 17.

Supplemental Content

Support Center